Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1953 2
1954 2
1956 1
1957 1
1958 2
1959 1
1960 2
1961 5
1962 4
1963 4
1964 2
1965 4
1966 1
1967 1
1970 1
1972 4
1973 10
1974 7
1976 7
1977 5
1978 8
1979 4
1980 4
1981 7
1982 3
1983 7
1984 5
1985 4
1986 3
1987 3
1988 2
1989 9
1990 5
1991 8
1992 3
1993 5
1994 8
1995 3
1996 12
1997 17
1998 9
1999 7
2000 11
2001 13
2002 12
2003 15
2004 13
2005 8
2006 12
2007 15
2008 13
2009 14
2010 14
2011 21
2012 17
2013 24
2014 22
2015 24
2016 21
2017 25
2018 28
2019 26
2020 33
2021 23
2022 13
Text availability
Article attribute
Article type
Publication date

Search Results

569 results
Results by year
Filters applied: . Clear all
Page 1
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF. Shaw AT, et al. Among authors: clancy js. J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20. J Clin Oncol. 2019. PMID: 30892989 Free PMC article. Clinical Trial.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: clancy js. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Shaw AT, Solomon BJ, Chiari R, Riely GJ, Besse B, Soo RA, Kao S, Lin CC, Bauer TM, Clancy JS, Thurm H, Martini JF, Peltz G, Abbattista A, Li S, Ou SI. Shaw AT, et al. Among authors: clancy js. Lancet Oncol. 2019 Dec;20(12):1691-1701. doi: 10.1016/S1470-2045(19)30655-2. Epub 2019 Oct 25. Lancet Oncol. 2019. PMID: 31669155 Clinical Trial.
CD25-Treg-depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Solomon I, Amann M, Goubier A, Arce Vargas F, Zervas D, Qing C, Henry JY, Ghorani E, Akarca AU, Marafioti T, Śledzińska A, Werner Sunderland M, Franz Demane D, Clancy JR, Georgiou A, Salimu J, Merchiers P, Brown MA, Flury R, Eckmann J, Murgia C, Sam J, Jacobsen B, Marrer-Berger E, Boetsch C, Belli S, Leibrock L, Benz J, Koll H, Sutmuller R, Peggs KS, Quezada SA. Solomon I, et al. Among authors: clancy jr. Nat Cancer. 2020 Dec;1(12):1153-1166. doi: 10.1038/s43018-020-00133-0. Epub 2020 Nov 9. Nat Cancer. 2020. PMID: 33644766 Free PMC article.
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Schwarzenberg SJ, Singh PK, Solomon GM, Stalvey MS, Clancy JP, Kirby S, Van Dalfsen JM, Kloster MH, Rowe SM; PROMISE Study group. Nichols DP, et al. Among authors: clancy jp. Am J Respir Crit Care Med. 2022 Mar 1;205(5):529-539. doi: 10.1164/rccm.202108-1986OC. Am J Respir Crit Care Med. 2022. PMID: 34784492 Free PMC article.
2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction.
Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R, Cha YM, Clancy J, Deharo JC, Ellenbogen KA, Exner D, Hussein AA, Kennergren C, Krahn A, Lee R, Love CJ, Madden RA, Mazzetti HA, Moore JC, Parsonnet J, Patton KK, Rozner MA, Selzman KA, Shoda M, Srivathsan K, Strathmore NF, Swerdlow CD, Tompkins C, Wazni O. Kusumoto FM, et al. Among authors: clancy j. Heart Rhythm. 2017 Dec;14(12):e503-e551. doi: 10.1016/j.hrthm.2017.09.001. Epub 2017 Sep 15. Heart Rhythm. 2017. PMID: 28919379 Review. No abstract available.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Shaw AT, et al. Among authors: clancy js. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074098 Free PMC article. Clinical Trial.
The ins and outs of microvesicles.
Clancy JW, Schmidtmann M, D'Souza-Schorey C. Clancy JW, et al. FASEB Bioadv. 2021 Mar 4;3(6):399-406. doi: 10.1096/fba.2020-00127. eCollection 2021 Jun. FASEB Bioadv. 2021. PMID: 34124595 Free PMC article. Review.
569 results